Absence of modulation of CD4+CD25high regulatory T cells in CTCL patients treated with bexarotene

Experimental Dermatology

Volumn 19, Issue 8, 2010, Pages

  Knol, Anne Chantal ^a   Quéreux, Gaëlle ^a,b   Brocard, Anabelle ^b   Ballanger, Fabienne ^b   Khammari, Amir ^a,b   Nguyen, Jean Michel ^c   Dréno, Brigitte ^a,b  

^a INSERM   (France)

^b CLINIQUE DERMATOLOGIQUE   (France)

^c CHU DE NANTES   (France)

Author keywords

Bexarotene; Cutaneous T cell lymphoma; Regulatory T cells

Indexed keywords

BEXAROTENE; CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL ISOLATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MYCOSIS FUNGOIDES; PHENOTYPE; REGULATORY T LYMPHOCYTE; SEZARY SYNDROME; SKIN BIOPSY; TREATMENT RESPONSE;

AGED; ANTICARCINOGENIC AGENTS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TETRAHYDRONAPHTHALENES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 77954848281     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2009.00993.x     Document Type: Article

References (43)

1. Olsen E, Vonderheid E, Pimpinelli N. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007, 110:1713-1722.
2. Hwang S T, Janik J E, Jaffe E S, Wilson W H. Mycosis fungoides and Sezary syndrome. Lancet 2008, 371:945-957.
3. Tessier-Marteau A, Le Corre Y, Gerard J. Peripheral blood Sezary cells and the diagnosis of Sezary syndrome. Ann Biol Clin (Paris) 2008, 66:447-453.
4. Miedema F, Willemze R, Terpstra F G, van Vloten W A, Meijer C J, Melief C J. Regulatory activity of neoplastic T cells in Sezary syndrome on in vitro immunoglobulin production. Leuk Res 1984, 8:873-884.
5. Berger C L, Tigelaar R, Cohen J. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood 2005, 105:1640-1647.
6. Krejsgaard T, Gjerdrum L M, Ralfkiaer E. Malignant Tregs express low molecular splice forms of FOXP3 in Sezary syndrome. Leukemia 2008, 22(12):2230-2239. Dec;
7. Hartmann T B, Mattern E, Wiedemann N. Identification of selectively expressed genes and antigens in CTCL. Exp Dermatol 2008, 17:324-334.
8. Stadler R, Otte H G, Luger T. Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998, 92:3578-3581.
9. Thomsen K, Molin L, Volden G, Lange Wantzin G, Hellbe L. 13-cis-retinoic acid effective in mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1984, 64:563-566.
10. Thomsen K, Hammar H, Molin L, Volden G. Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1989, 69:536-538.
11. Fitzpatrick J E, Mellette J R. Treatment of mycosis fungoides with isotretinoin. J Dermatol Surg Oncol 1986, 12:626-629.
12. Kessler J F, Jones S E, Levine N, Lynch P J, Booth A R, Meyskens F L. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol 1987, 123:201-204.
13. Miller V A, Benedetti F M, Rigas J R. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 1997, 15:790-795.
14. Prince H M, McCormack C, Ryan G. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australas J Dermatol 2001, 42:91-97.
15. Duvic M, Hymes K, Heald P. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001, 19:2456-2471.
16. Duvic M, Martin A G, Kim Y. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001, 137:581-593.
17. Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens V J. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 2002, 138:325-332.
18. Zhang C, Hazarika P, Ni X, Weidner D A, Duvic M. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002, 8:1234-1240.
19. Budgin J B, Richardson S K, Newton S B. Biological effects of bexarotene in cutaneous T-cell lymphoma. Arch Dermatol 2005, 141:315-321.
20. Bouwhuis S A, Davis M D, el-Azhary R A. Bexarotene treatment of late-stage mycosis fungoides and Sezary syndrome: development of extracutaneous lymphoma in 6 patients. J Am Acad Dermatol 2005, 52:991-996.
21. Benson M J, Pino-Lagos K, Rosemblatt M, Noelle R J. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med 2007, 204:1765-1774.
22. Coombes J L, Siddiqui K R, Arancibia-Carcamo C V. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 2007, 204:1757-1764.
23. Kang S G, Lim H W, Andrisani O M, Broxmeyer H E, Kim C H. Vitamin A metabolites induce gut-homing FoxP3+ regulatory T cells. J Immunol 2007, 179:3724-3733.
24. Mucida D, Park Y, Kim G, Turovskaya O. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007, 317:256-260.
25. Sun C M, Hall J A, Blank R B. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med 2007, 204:1775-1785.
26. Schambach F, Schupp M, Lazar M A, Reiner S L. Activation of retinoic acid receptor-alpha favours regulatory T cell induction at the expense of IL-17-secreting T helper cell differentiation. Eur J Immunol 2007, 37:2396-2399.
27. Kim Y H, Willemze R, Pimpinelli N. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007, 110:479-484.
28. Vonderheid E C, Bernengo M G, Burg G. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002, 46:95-106.
29. Jarrousse V, Quereux G, Marques-Briand S, Knol A C, Khammari A, Dreno B. Toll-like receptors 2, 4 and 9 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Eur J Dermatol 2006, 16:636-641.
30. Sakaguchi S, Sakaguchi N, Shimizu J. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001, 182:18-32.
31. Shevach E M. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002, 2:389-400.
32. Shevach E M, McHugh R S, Piccirillo C A, Thornton A M. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev 2001, 182:58-67.
33. Knol A C, Lemaitre F, Pandolfino M C. Absence of amplification of CD4+CD25(high) regulatory T cells during in vitro expansion of tumor-infiltrating lymphocytes in melanoma patients. Exp Dermatol 2008, 17:436-445.
34. Viguier M, Lemaitre F, Verola O. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004, 173:1444-1453.
35. Gjerdrum L M, Woetmann A, Odum N. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 2007, 21:2512-2518.
36. Klemke C D, Fritzsching B, Franz B. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sezary syndrome from other cutaneous T-cell lymphomas. Leukemia 2006, 20:1123-1129.
37. Rensing-Ehl A, Gaus B, Bruckner-Tuderman L, Martin S F. Frequency, function and CLA expression of CD4+CD25+FOXP3+ regulatory T cells in bullous pemphigoid. Exp Dermatol 2007, 16:13-21.
38. Dejaco C, Duftner C, Schirmer M. Are regulatory T-cells linked with aging? Exp Gerontol 2006, 41:339-345.
39. Tiemessen M M, Mitchell T J, Hendry L, Whittaker S J, Taams L S, John S. Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma. J Invest Dermatol 2006, 126:2217-2223.
40. Capriotti E, Vonderheid E C, Thoburn C J, Wasik M A, Bahler D W, Hess A D. Expression of T-plastFoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma. Leuk Lymphoma 2008, 49:1190-1201.
41. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
42. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000, 101:455-458.
43. Berger C L, Hanlon D, Kanada D. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood 2002, 99:2929-2939.